瑞士批准抗抗性高血压新药JERAYGO,这是30多年来针对一条新途径的首例。 Switzerland approves JERAYGO, a new drug for resistant hypertension, the first in over 30 years targeting a novel pathway.

瑞士已批准Idorsia's JERAYGO(aProcitentan)治疗成人抗性高血压,标志着30多年来首次针对新途径的系统性高血压新治疗。 Switzerland has approved Idorsia's JERAYGO (aprocitentan) for treating resistant hypertension in adults, marking the first new systemic hypertension treatment targeting a novel pathway in over 30 years. 它是该国批准用于这一用途的第一种也是唯一一种内分泌受体对抗者,针对的病人至少已经使用三种抗血压药物。 It is the first and only endothelin receptor antagonist approved in the country for this use, intended for patients already on at least three antihypertensive drugs. 该药物每日口服一次,剂量为12.5毫克(可能增加到25毫克),在PRECISION第3阶段试验中显示血压显著下降。 The drug, taken orally once daily at 12.5 mg (with a possible increase to 25 mg), showed significant blood pressure reductions in the Phase 3 PRECISION trial. 此项核准突出了在解决抗抗性高血压方面的一大进步,抗性高血压是全世界早期疾病和死亡的一个主要风险因素。 The approval highlights a major advancement in addressing resistant hypertension, a leading risk factor for early illness and death worldwide.